MedPath

FDA Grants Early Approval to Revuforj (revumenib) for Acute Leukemia Treatment, Boosting Syndax Pharmaceuticals

• The FDA has granted early approval to Revuforj (revumenib) for specific acute leukemias, a significant milestone for Syndax Pharmaceuticals. • Analysts predict favorable pricing for Revuforj, suggesting strong revenue prospects and a positive outlook for its safety and efficacy. • Recent positive data regarding NPM1 and upcoming updates at the ASH conference further support Revuforj's potential in leukemia treatment. • Goldman Sachs and J.P. Morgan maintain a Buy rating on Syndax Pharmaceuticals (SNDX), citing the promising long-term potential of Revuforj.

The FDA has granted early approval to Revuforj (revumenib) for the treatment of certain acute leukemias, marking a significant achievement for Syndax Pharmaceuticals. This decision, earlier than anticipated, validates the company's communications with the FDA and highlights the potential of Revuforj in the market.

Analyst Perspectives

J.P. Morgan analyst Anupam Rama has reiterated an Overweight rating on Syndax Pharmaceuticals (SNDX), emphasizing the promising long-term potential of Revuforj in treating acute leukemias. The analyst's bullish stance is underpinned by the early FDA approval and favorable pricing strategy for Revuforj, which is expected to drive strong revenue. Goldman Sachs also maintains a Buy rating on the stock with a $31.00 price target.

Clinical and Scientific Support

Recent positive data concerning NPM1, along with upcoming updates at the ASH conference, are expected to further bolster the positive outlook for Revuforj's safety and efficacy. These developments provide additional confidence in the drug's potential to address unmet needs in acute leukemia treatment.

Company Profile

Syndax Pharmaceuticals, Inc., founded in 2005 and headquartered in Waltham, MA, is focused on developing cancer therapies. Revuforj (revumenib) represents a key asset in their portfolio, demonstrating the company's commitment to innovative treatments in oncology.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves Revuforj (axatilimab) for Relapsed or Refractory Chronic Graft-versus-Host Disease

The FDA has granted approval to Revuforj (axatilimab) for the treatment of adult and pediatric patients 12 years and older with relapsed or refractory chronic graft-versus-host disease (cGVHD) after failure of one or two prior lines of systemic therapy.
Axatilimab, developed by Syndax Pharmaceuticals, is a novel, intravenously administered antibody that targets colony stimulating factor 1 receptor (CSF-1R), a key regulator of monocyte and macrophage function.

FDA Approves Syndax's Revuforj, a First-in-Class Menin Inhibitor for Acute Leukemia

The FDA has approved Syndax Pharmaceuticals' Revuforj (revumenib) for adults and children with relapsed or refractory acute leukemia with KMT2A rearrangement.
Revuforj, a menin inhibitor, showed a complete remission or complete remission with partial hematologic recovery in 21.2% of study participants, with a median response duration of 6.4 months.

Syndax's Revuforj (revumenib) Receives FDA Approval for KMT2A-Rearranged Acute Leukemia

The FDA has approved Syndax Pharmaceuticals' Revuforj (revumenib) as the first menin inhibitor for relapsed or refractory KMT2A-rearranged acute leukemia in adults and pediatric patients.
Revuforj demonstrated a complete remission rate of over 20% in clinical trials, with 23% of patients proceeding to stem cell transplant after treatment.

Syndax Pharmaceuticals' Revuforj Receives FDA Approval for Acute Leukemia with KMT2A Translocation

Syndax Pharmaceuticals' Revuforj (revumenib) has gained FDA approval for treating acute leukemia in adult and pediatric patients with KMT2A translocation.
The approval was based on Phase 1/2 AUGMENT-101 trial data, demonstrating a 21% complete response rate and a median response duration of 6.4 months.

FDA Approves Syndax's Revuforj as First Menin Inhibitor for KMT2A-Rearranged Leukemia

The FDA has granted priority review and approval to Syndax Pharmaceuticals' Revuforj (revumenib) for relapsed or refractory acute leukemia with KMT2A translocations.
Revuforj is the first FDA-approved menin inhibitor, marking a significant advancement in treating this aggressive form of leukemia in patients aged one year and older.

Zevra Therapeutics Receives Buy Rating Following FDA Approval of Miplyffa for Niemann-Pick Disease Type C

Zevra Therapeutics maintains a Buy rating due to its strong financial position, including $95.5 million in cash reserves expected to support operations until 2027.
The FDA's approval of Miplyffa for Niemann-Pick disease type C (NPC) positions Zevra to capitalize on a lucrative market, further boosted by a Priority Review Voucher.

Disc Medicine's Bitopertin Gains Momentum with Positive Regulatory Feedback and Analyst Upgrades

Disc Medicine received positive feedback from the FDA regarding bitopertin for erythropoietic protoporphyria (EPP), potentially allowing for accelerated approval based on PPIX reduction.
Analyst ratings for Disc Medicine have been upgraded to 'Strong Buy' by Raymond James, with a price target of $110, citing the accelerated timeline for bitopertin's launch.

Syndax Pharmaceuticals' Niktimvo Approved for cGVHD, Revumenib Awaits FDA Decision

Syndax Pharmaceuticals' Niktimvo (anti-CSF1R) received FDA approval for chronic Graft versus Host Disease (cGVHD) treatment, marking a significant milestone for the company.
The PDUFA date for Syndax's revumenib, a menin inhibitor for KMT2A-rearranged acute myeloid leukemia (AML), is set for December 26, 2024.

Sangamo Therapeutics' Fabry Disease Candidate ST-920 Gains Accelerated Approval Pathway

Sangamo Therapeutics' shares surged after the FDA agreed to a regulatory pathway for accelerated approval of isaralgagene civaparvovec (ST-920) for Fabry disease.
The FDA will consider data from the Phase I/II STAAR trial, using the rate of decline in eGFR at 52 weeks as the primary basis for approval.

FDA Lifts Partial Hold on Avidity Biosciences' Myotonic Dystrophy Drug, Stock Surges

The FDA has lifted a partial clinical hold on Avidity Biosciences' delpacibart etedesiran (AOC 1001), a drug targeting myotonic dystrophy type 1, allowing patient recruitment for the Phase 3 trial to resume.
Following the FDA's decision, Avidity Biosciences' stock (RNA) experienced a 0.53% increase, reaching $47.30, signaling positive investor response to the advancement of AOC 1001.

Reference News

[1]
Early FDA Approval of Revuforj Boosts Syndax Pharmaceuticals' Prospects and Supports ...
markets.businessinsider.com · Nov 17, 2024

J.P. Morgan analyst Anupam Rama maintains bullish stance on SNDX stock, citing FDA early approval of Revuforj for acute ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy